NKT cells as an ideal anti-tumor immunotherapeutic

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Fujii, Shin ichiro ^a   Shimizu, Kanako ^a   Okamoto, Yoshitaka ^b   Kunii, Naoki ^b   Nakayama, Toshinori ^b   Motohashi, Shinichiro ^b   Taniguchi, Masaru ^a  

^a RIKEN Center for Integrative Medical Sciences   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Adjuvant effects; Artificial adjuvant vector cells; Clinical trial; Induced pluripotent stem cells; NKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; AMINO ACID SUBSTITUTION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL EXPANSION; CELL INFILTRATION; CELL MATURATION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HEAD AND NECK TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PLURIPOTENT STEM CELL; SHORT SURVEY;

EID: 84892171393     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00409     Document Type: Short Survey

References (45)

1. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol (2003) 21:483-513. doi:10.1146/annurev.immunol.21.120601.141057.
2. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol (2004) 4(3):231-7. doi:10.1038/nri1309.
3. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol (2007) 25:297-336. doi:10.1146/annurev.immunol.25.022106.141711.
4. Imai K, Kanno M, Kimoto H, Shigemoto K, Yamamoto S, Taniguchi M. Sequence and expression of transcripts of the T-cell antigen receptor alpha-chain gene in a functional, antigen-specific suppressor-T-cell hybridoma. Proc Natl Acad Sci U S A (1986) 83(22):8708-12. doi:10.1073/pnas.83.22.8708.
5. Koseki H, Imai K, Ichikawa T, Hayata I, Taniguchi M. Predominant use of a particular alpha-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. Int Immunol (1989) 1(6):557-64. doi:10.1093/intimm/1.6.557.
6. Koseki H, Imai K, Nakayama F, Sado T, Moriwaki K, Taniguchi M. Homogenous junctional sequence of the V14+ T-cell antigen receptor alpha chain expanded in unprimed mice. Proc Natl Acad Sci U S A (1990) 87(14):5248-52. doi:10.1073/pnas.87.14.5248.
7. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science (1997) 278:1623-6. doi:10.1126/science.278.5343.1623.
8. Adachi Y, Koseki H, Zijlstra M, Taniguchi M. Positive selection of invariant V alpha 14+ T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells. Proc Natl Acad Sci U S A (1995) 92(4):1200-4. doi:10.1073/pnas.92.4.1200.
9. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science (1997) 277(5324):339-45. doi:10.1126/science.277.5324.339.
10. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science (1997) 278:1626-9. doi:10.1126/science.278.5343.1626.
11. Kawano T, Tanaka Y, Shimizu E, Kaneko Y, Kamata N, Sato H, et al. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int Immunol (1999) 11(6):881-7. doi:10.1093/intimm/11.6.881.
12. Borg NA, Wun KS, Kjer-Nielsen L, Wilce MC, Pellicci DG, Koh R, et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature (2007) 448(7149):44-9. doi:10.1038/nature05907.
13. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med (1998) 188:1529-34. doi:10.1084/jem.188.8.1529.
14. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T Cells is highly conserved through mammalian evolution. J Exp Med (1998) 188:1521-8. doi:10.1084/jem.188.8.1521.
15. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol (2004) 22:817-90. doi:10.1146/annurev.immunol.22.012703.104608.
16. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol (2003) 4(12):1164-5. doi:10.1038/ni1203-1164.
17. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J Exp Med (2003) 198(2):267-79. doi:10.1084/jem.20030324.
18. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol (2003) 171:5140-7.
19. Eberl G, Brawand P, MacDonald HR. Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. J Immunol (2000) 165(8):4305-11.
20. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity (2000) 12:211-21. doi:10.1016/S1074-7613(00)80174-0.
21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12(4):252-64. doi:10.1038/nrc3239.
22. Fujii S, Goto A, Shimizu K. Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood (2009) 113(18):4262-72. doi:10.1182/blood-2008-08-176446.
23. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 14(6):e218-28. doi:10.1016/S1470-2045(12)70582-X.
24. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med (2004) 199(12):1607-18. doi:10.1084/jem.20040317.
25. Akutsu Y, Nakayama T, Harada M, Kawano T, Motohashi S, Shimizu E, et al. Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res (2002) 93(4):397-403. doi:10.1111/j.1349-7006.2002.tb01270.x.
26. Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, et al. Preserved IFN-γ production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer (2002) 102(2):159-65. doi:10.1002/ijc.10678.
27. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol (1999) 163:2387-91.
28. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol (2009) 182(4):2492-501. doi:10.4049/jimmunol.0800126.
29. Ishikawa E, Motohashi S, Ishikawa A, Ito T, Uchida T, Kaneko T, et al. Dendritic cell maturation by CD11c-T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide. Int J Cancer (2005) 117(2):265-73. doi:10.1002/ijc.21197.
30. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res (2005) 11(5):1910-7. doi:10.1158/1078-0432.CCR-04-1453.
31. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res (2006) 12(20 Pt 1):6079-86. doi:10.1158/1078-0432.CCR-06-0114.
32. Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol (2011) 140(2):167-76. doi:10.1016/j.clim.2011.01.009.
33. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci (2008) 99(4):638-45. doi:10.1111/j.1349-7006.2008.00730.x.
34. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol (1999) 163(9):4647-50.
35. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, et al. Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood (2002) 99:1259-66. doi:10.1182/blood.V99.4.1259.
36. Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, et al. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells. J Clin Immunol (2012) 32(5):1071-81. doi:10.1007/s10875-012-9697-9.
37. Mountain CF. Revisions in the international system for staging lung cancer. Chest (1997) 111(6):1710-7. doi:10.1378/chest.111.6.1710.
38. Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am (2003) 9(2):207-36. doi:10.1016/S1078-5337(02)00089-8.
39. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol (2000) 18(10):2095-103.
40. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol (2000) 18(21):3722-30.
41. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol (2011) 138(3):255-65. doi:10.1016/j.clim.2010.11.014.
42. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126(4):663-76. doi:10.1016/j.cell.2006.07.024.
43. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature (2007) 448(7151):313-7. doi:10.1038/nature05934.
44. Watarai H, Fujii S, Yamada D, Rybouchkin A, Sakata S, Nagata Y, et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J Clin Invest (2010) 120(7):2610-8. doi:10.1172/JCI42027.
45. Shimizu K, Asakura M, Shinga J, Sato Y, Kitahara S, Hoshino K, et al. Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol (2013) 190(11):5609-19. doi:10.4049/jimmunol.1300033.